ArticleBritish journal of cancer1990
Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer.
Article in British journal of cancer, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.Breast cancer research : BCR · 2012Trial
- Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.Pathology oncology research : POR · 2005Trial
- Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy.Nature communications · 2025Article
- Identification of Immune Cell Components in Breast Tissues by a Multiparametric Flow Cytometry Approach.Cancers · 2022Article
- The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression.Scientific reports · 2022Article
- Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.EMBO molecular medicine · 2021Article
- Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.JCI insight · 2019Article
- Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.Oncotarget · 2017Observational
- Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.Journal of translational medicine · 2016Article
- The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts.Acta oncologica (Stockholm, Sweden) · 2013Article
- CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate.PloS one · 2012Article
- Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.Cellular & molecular immunology · 2011Article
- EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions.British journal of cancer · 2001Article
- Gene therapy for carcinoma of the breast: Genetic immunotherapy.Breast cancer research : BCR · 2000Review
- Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.Clinical and experimental immunology · 2000Article
- High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours.British journal of cancer · 1997Article
- Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4.British journal of cancer · 1996Article
- In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.Annals of surgical oncology · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 31 patients with carcinoma of the breast the phenotype and activation status of tumour infiltrating lymphocytes (TILs) was analysed by flow cytometry. The predominant cells, in all patients, were T lymphocytes and in the majority of cases CD8+ (cytotoxic/suppressor) T lymphocytes were present in greater numbers than CD4+ (helper) T lymphocytes. There was no relationship between the degree of lymphocytic infiltration and either tumour stage or grade but there appeared to be an inverse correlation with the levels of oestrogen receptor (ER) in the tumour (P less than 0.01). Both populations of T cells had significantly higher numbers of cells carrying HLA DR (class II major histocompatibility antigen) than the equivalent populations in peripheral blood from the same patient group (P less than 0.001). The transferrin receptor was found on similar numbers of CD8+ T cells in peripheral blood and among the tumour infiltrating lymphocytes while more of the CD4+ T cells infiltrating the tumour were found to carry this receptor (P = 0.034). The Tac (CD 25) antigen was also on similar numbers of CD8+ T cells from both peripheral blood and the tumour but was on fewer of the CD4+ T cells in the tumour with respect to peripheral blood (P = 0.029). In both TILs and blood lymphocytes, the Tac antigen was consistently present on greater numbers of CD4+ T lymphocytes than on the CD8+ T lymphocytes (P less than 0.001) and as this is a component of the interleukin 2 (IL-2) receptor this may be of relevance to the use of IL-2 in TIL cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.